These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

575 related articles for article (PubMed ID: 27009796)

  • 1. Systematic review of the economic evaluations of novel therapeutic agents in multiple myeloma: what is the reporting quality?
    Aguiar PM; Lima TM; Storpirtis S
    J Clin Pharm Ther; 2016 Apr; 41(2):189-97. PubMed ID: 27009796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.
    Möller J; Nicklasson L; Murthy A
    J Med Econ; 2011; 14(6):690-7. PubMed ID: 21892856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden.
    Borg S; Nahi H; Hansson M; Lee D; Elvidge J; Persson U
    Acta Oncol; 2016 May; 55(5):554-60. PubMed ID: 27123742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic Evaluations of Anticancer Drugs Based on Medico-Administrative Databases: A Systematic Literature Review.
    Bouée-Benhamiche E; Bousquet PJ; Ghabri S
    Appl Health Econ Health Policy; 2020 Aug; 18(4):491-508. PubMed ID: 32056121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluations on the use of aripiprazole for patients with schizophrenia: A systematic review.
    Henrique ICB; de Mendonça Lima T; de Melo DO; Aguiar PM
    J Clin Pharm Ther; 2020 Feb; 45(1):1-15. PubMed ID: 31436857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic value.
    Gaultney JG; Redekop WK; Sonneveld P; Uyl-de Groot CA
    Expert Rev Anticancer Ther; 2012 Jun; 12(6):839-54. PubMed ID: 22716498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective.
    Jakubowiak AJ; Campioni M; Benedict Á; Houisse I; Tichy E; Giannopoulou A; Aggarwal SK; Barber BL; Panjabi S
    J Med Econ; 2016 Nov; 19(11):1061-1074. PubMed ID: 27224006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma.
    Blommestein HM; Franken MG; van Beurden-Tan CHY; Blijlevens NMA; Huijgens PC; Sonneveld P; Uyl-de Groot CA; Zweegman S
    JAMA Netw Open; 2021 Mar; 4(3):e213497. PubMed ID: 33779744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spotlight on lenalidomide in relapsed or refractory multiple myeloma.
    Scott LJ; Lyseng-Williamson KA
    BioDrugs; 2011 Oct; 25(5):333-7. PubMed ID: 21942918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic Literature Review of Economic Evaluations of Biological Treatment Sequences for Patients with Moderate to Severe Rheumatoid Arthritis Previously Treated with Disease-Modifying Anti-rheumatic Drugs.
    Ghabri S; Lam L; Bocquet F; Spath HM
    Pharmacoeconomics; 2020 May; 38(5):459-471. PubMed ID: 32052376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs.
    Gooding S; Lau IJ; Sheikh M; Roberts P; Wong J; Dickens E; Bullement A; Elvidge J; Lee D; Ramasamy K
    PLoS One; 2015; 10(9):e0136207. PubMed ID: 26367874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review of economic evaluations of treatment regimens in multiple myeloma.
    Asrar MM; Lad DP; Prinja S; Bansal D
    Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):799-809. PubMed ID: 32496881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential therapeutic and economic value of risk-stratified treatment as initial treatment of multiple myeloma in Europe.
    Gaultney JG; Ng TW; Uyl-de Groot CA; Sonneveld P; van Beers EH; van Vliet MH; Redekop WK
    Pharmacogenomics; 2018 Feb; 19(3):213-226. PubMed ID: 29334316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacoeconomics Evaluations of Oral Anticancer Agents: Systematic Review of Characteristics, Methodological Trends, and Reporting Quality.
    Al Kadour A; Marridi WA; Al-Badriyeh D
    Value Health Reg Issues; 2018 Sep; 16():46-60. PubMed ID: 30144775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.
    Usmani SZ; Cavenagh JD; Belch AR; Hulin C; Basu S; White D; Nooka A; Ervin-Haynes A; Yiu W; Nagarwala Y; Berger A; Pelligra CG; Guo S; Binder G; Gibson CJ; Facon T
    J Med Econ; 2016; 19(3):243-58. PubMed ID: 26517601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents.
    Gaultney JG; Franken MG; Tan SS; Redekop WK; Huijgens PC; Sonneveld P; Uyl-de Groot CA
    J Clin Pharm Ther; 2013 Feb; 38(1):41-7. PubMed ID: 23126374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
    Papaioannou D; Rafia R; Rathbone J; Stevenson M; Buckley Woods H; Stevens J
    Health Technol Assess; 2012; 16(37):1-253, iii-iv. PubMed ID: 23021127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical review of economic evaluations in multiple myeloma: an overview of the economic evidence and quality of the methodology.
    Gaultney JG; Redekop WK; Sonneveld P; Uyl-de Groot CA
    Eur J Cancer; 2011 Jul; 47(10):1458-67. PubMed ID: 21561761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Treatment Options for Neuropathic Pain: a Systematic Review.
    Ruiz-Negrón N; Menon J; King JB; Ma J; Bellows BK
    Pharmacoeconomics; 2019 May; 37(5):669-688. PubMed ID: 30637713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study.
    Armoiry X; Fagnani F; Benboubker L; Facon T; Fermand JP; Hulin C; Moreau P; Aulagner G
    J Clin Pharm Ther; 2011 Feb; 36(1):19-26. PubMed ID: 21198717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.